MYH14 and nemaline myopathy: Moving forward, there are some pathways, such as ubiquitination/protein turnover and actin-myosin cross bridge dynamics (de Winter et al., 2013; Ramirez-Martinez et al., 2017), that have been identified in models of other NM genetic subtypes that may yield targeted therapies for NEB-related NM.